Non-invasive Goal-directed thErapy oN cIrcUlatory Shock

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Sao Paulo

About this trial

Circulatory shock occurs when the oxygen supply to the tissues decreases, leading to cellular damage and affecting about one-third of patients admitted to Intensive Care Units (ICUs). Cardiac Output (CO) is defined as the volume of blood ejected by the left ventricle per minute and is a crucial hemodynamic parameter for monitoring patients with signs of circulatory shock. However, this parameter is underutilized in patients treated in Emergency Units because its measurement typically involves invasive methods, which are not commonly available in this setting. Any method capable of measuring CO without the need for pulmonary artery catheter insertion is referred to as minimally invasive CO monitoring. Evaluating these parameters allows for a quicker determination of the etiology of circulatory shock, enabling the early initiation of goal-directed therapy. Goal-directed therapy has been proven effective in reducing morbidity and mortality, ICU length of stay, and mechanical ventilation duration in ICU patients who respond to fluid resuscitation. Currently, there are no data on the impact of a hemodynamic optimization strategy in patients during the early hours of shock.

The objective is to assess whether goal-directed hemodynamic therapy, through non-invasive hemodynamic monitoring, reduces the time required for hemodynamic resuscitation in patients with septic shock. A multicenter, randomized, open-label study will be conducted in Emergency Units, Intensive Care Units, and Hospital Wards.

Patients over 18 years old admitted with signs of septic shock (defined as systolic blood pressure less than 90 mmHg and/or mean arterial pressure less than 65 mmHg, along with at least one of the following criteria: lactate greater than 2 mEq/L, oliguria, neurological alteration, or capillary refill time greater than 3 seconds) will be included Participants will be randomized in a 1:1 ratio into two groups. In the Goal-Directed Therapy Group, patients will be monitored using the HemoSphere HPI™ (Edwards Life Sciences, Irvine, CA, USA), where parameters such as cardiac index (CI), stroke volume (SV), systolic blood pressure (SBP), mean arterial pressure (MAP), and HPI will guide medical management. In the Conventional Therapy Group, patients will be evaluated with the standard hemodynamic monitoring equipment typically found in emergency units..

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age > 18 years;

Lactate > 2 mEq/L;

Oliguria (urine output < 0.5 mL/kg/h for at least 6 hours);

Neurological changes (mental confusion, decreased level of consciousness, psychomotor agitation, temporal-spatial disorientation);

Disqualifiers

Hospital admission time greater than 24 hours

Significant edema in the fingers

Severe peripheral vasoconstriction

Use of Norepinephrine at a dose greater than or equal to 0.5 mcg/kg/min

Trial design

Design model

Parallel

Treatments tested in this trial

  • Goal-Directed Therapy

    Device

    Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg. If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell.

Treatment groups

380 Participants
are divided into 2 treatment groups
Group A: Goal-Directed Therapy GroupExperimental treatment 1 intervention
Group B: Conventional Therapy GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Time to Resuscitation after 6 hours of treatment

Time to Resuscitation: After 6 hours of treatment, the number of patients who achieve the following goals: Mean arterial pressure \> 65mmHg Urine output greater than 0.5 mL/kg/h for more than 2 hours, and/or Decrease of more than 10% in serum lactate compared to the initial value

Time frame
6 hours

Secondary outcomes

1

Number of Participants with Myocardial Injury

Presence of elevated troponin levels to values above the 99th percentile.

Time frame
30 days
2

Number of Participants with Acute Myocardial Infarction

Presence of Myocardial Injury, associated with at least one of the following factors: * Symptoms of acute myocardial ischemia; * Dynamic alteration on Electrocardiogram; * Evidence of new myocardial segmental contractility loss, diagnosed by Echocardiogram and/or Cardiac Resonance.

Time frame
30 days
3

Patients with Acute Kidney Injury

Number of patients with Acute Kidney Injury within 72 hours

Time frame
72 hours
4

Assessment of health costs

The health costs will be measured in US dollars using the Brazilian Public Health database, which contains data on procedures, medicines, and hospital stay prices.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Sao Paulo

Lead sponsor

Instituto Dante Pazzanese de Cardiologia

Collaborator